Literature DB >> 24628551

Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study.

J C Rousseau1, E Sornay-Rendu, C Bertholon, R Chapurlat, P Garnero.   

Abstract

PURPOSE: Periostin (POSTN) is a secreted γ-carboxyglutamic acid-containing protein expressed mainly in the periosteum in adult individuals. POSNT deficient mice develop periodontis and osteoporosis with decreased bone strength. The relationship between serum POSTN and bone metabolism and fracture risk in postmenopausal women is unknown. SUBJECTS AND METHODS: Serum POSTN was measured in 607 postmenopausal women (mean age 66.6 ± 8.4 y) from the Os des Femmes de Lyon cohort at the ninth annual follow-up visit (baseline visit of the current analysis). Nonvertebral and clinical vertebral incident fragility fractures were reported annually during 7 years. Areal bone mineral density (BMD; measured by dual energy X-ray absorptiometry) of the hip and bone markers (intact N-terminal propeptide of type I collagen, osteocalcin, and serum type I collagen C-telopeptide) were also measured.
RESULTS: At baseline, serum POSTN did not correlate with age, bone markers, and BMD. After a median of 7 years of follow-up, 75 women sustained an incident clinical vertebral or nonvertebral fragility fracture. The proportion of women who had an incident fracture was significantly higher in women with levels of POSTN in the highest quartile than that of women in the three other quartiles (19.5% vs 10.1%, P = .018) after adjustment for age and prevalent fracture. The highest quartile of POSTN was associated with an increased risk of incident fracture with a relative risk (95% confidence interval) of 1.88 (1.1-3.2) after adjustment for age, prevalent fracture, and hip BMD T-score. Patients with both low hip BMD (T-score < -2.5) and high levels of POSTN (fourth quartile) had a relative risk of fracture of 7.1 (95% confidence interval 2.4-21.8) after adjustment for age.
CONCLUSION: High serum POSTN levels are independently associated with increased fracture risk in postmenopausal women. These data suggest that serum POSTN could be useful to improve fracture risk assessment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24628551     DOI: 10.1210/jc.2013-3893

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  Periostin on the road to nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis
Journal:  Endocrine       Date:  2015-11-19       Impact factor: 3.633

Review 2.  Role of pancreatic stellate cells and periostin in pancreatic cancer progression.

Authors:  Yang Liu; Lianfang Du
Journal:  Tumour Biol       Date:  2015-04-04

3.  Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.

Authors:  Fatma Gossiel; Jessica R Scott; Margaret A Paggiosi; Kim E Naylor; Eugene V McCloskey; Nicola F A Peel; Jennifer S Walsh; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

Review 4.  The Utility of Biomarkers in Osteoporosis Management.

Authors:  Patrick Garnero
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

5.  Interaction between LRP5 and periostin gene polymorphisms on serum periostin levels and cortical bone microstructure.

Authors:  J Pepe; N Bonnet; F R Herrmann; E Biver; R Rizzoli; T Chevalley; S L Ferrari
Journal:  Osteoporos Int       Date:  2017-10-16       Impact factor: 4.507

6.  Association of circulating dipeptidyl-peptidase 4 levels with osteoporotic fracture in postmenopausal women.

Authors:  H Kim; K H Baek; S-Y Lee; S H Ahn; S H Lee; J-M Koh; Y Rhee; C H Kim; D-Y Kim; M-I Kang; B-J Kim; Y-K Min
Journal:  Osteoporos Int       Date:  2016-11-19       Impact factor: 4.507

7.  Periostin and sclerostin levels in juvenile Paget's disease.

Authors:  Stergios A Polyzos; Polyzois Makras; Athanasios D Anastasilakis; Gesthimani Mintziori; Marina Kita; Athanasios Papatheodorou; Panagiotis Kokkoris; Evangelos Terpos
Journal:  Clin Cases Miner Bone Metab       Date:  2017-10-25

8.  Circulating periostin levels increase in association with bone density loss and healing progression during the early phase of hip fracture in Chinese older women.

Authors:  J Yan; H J Liu; H Li; L Chen; Y Q Bian; B Zhao; H X Han; S Z Han; L R Han; D W Wang; X F Yang
Journal:  Osteoporos Int       Date:  2017-04-05       Impact factor: 4.507

9.  Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study.

Authors:  Jin-Zhou Zhu; Hua-Tuo Zhu; Yi-Ning Dai; Chun-Xiao Li; Zhi-Yun Fang; De-Jian Zhao; Xing-Yong Wan; Yu-Ming Wang; Fang Wang; Chao-Hui Yu; You-Ming Li
Journal:  Endocrine       Date:  2015-09-11       Impact factor: 3.633

10.  Are bone turnover markers associated with volumetric bone density, size, and strength in older men and women? The AGES-Reykjavik study.

Authors:  E A Marques; V Gudnason; G Sigurdsson; T Lang; F Johannesdottir; K Siggeirsdottir; L Launer; G Eiriksdottir; T B Harris
Journal:  Osteoporos Int       Date:  2015-12-02       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.